K. Sakai et al. / Tetrahedron: Asymmetry 15 (2004) 3495–3500
3499
˚
1348, 1328, 1194, 1084, 1060, 933, 811, 778, 740, 702,
618; H NMR (400MHz, DMSO-d6): d 7.16–7.40 (m,
a = 6.135(1), b = 11.901(2), c = 27.907(5)A, V =
2037.5(6)A , Z = 4, Dcalc = 1.243g/cm3, R = 0.042;
1
3
˚
10H), 7.00 (d, J = 8.0Hz, 2H), 6.91 (d, J = 8.0Hz,
2H), 4.65 (s, 1H), 4.28 (dd, J = 8.8, 5.6Hz, 1H), 3.11
(dd, J = 13.2, 5.6Hz, 1H), 2.95 (dd, J = 13.2, 8.8Hz,
1H), 2.21 (s, 3H). Anal. Calcd for C23H25NO3ÆH2O: C,
72.42; H, 7.13; N, 3.67. Found C, 73.32; H, 7.08; N,
3.70.
Rw = 0.042. Number of reflections measured = total
2052, unique 1550.
References
1. Rouhi, A. M. Chemical and Engineering News 2003 (May
5), 46.
The mother liquor obtained after the first resolution de-
scribed above was evaporated to dryness to give a con-
densate [3.17g; (R)-enantiomer rich 49% de; water
contents 0.14% measured by KF method]. To the con-
densate was added ethanol (21.3g), the slurry was trans-
ferred to a 50mL flask. The mixture was stirred and
heated up to about 60ꢁC to give a clear solution. The
solution was then gradually cooled, seeded (2mg) at
25ꢁC, kept for 1h at around the crystallization temper-
ature and then cooled again to 20ꢁC. After aging the
suspension at the temperature for 1h, the crystals were
filtered off and washed twice with ethanol to afford the
crude (R)-1Æ(S)-2 salt (1.20g, 3.3mmol, 23% yield, 98%
de, E 46%). Analytical data for the recrystallized salt
are as follows.
2. (a) Indinavir: Merck Index, 13ed., No. 4970, 2001; (b)
Murakami, H.; Tobiyama, T.; Sakai, K. JP Kokai 1997-
48762; (c) Murakami, H.; Satoh, S.; Tobiyama, T.; Sakai,
K.; Nohira, H. EP 710652, 1996; (d) Murakami, H.;
Satoh, S.; Tobiyama, T.; Sakai, K.; Nohira, H. USP
5792869, 1996; Chem. Abstr. 1996, 125, 87209, resolution
of (S)-3-tert-butylcarbamoylpiperazine-1-carboxylic acid
tert-butyl ester with N-tosyl-(S)-phenylalanine.
3. (a) Sertraline: Merck Index, 13ed., No. 8541, 2001; (b)
Quallich, G. J. USP 6593496, 2000; Chem. Abstr. 2000,
134, 41980; (c) Mendelovici, M.; Nidam, T.; Pilarsky, G.;
Gershon, N. USP 6552227, 2001; Chem. Abstr. 2001, 135,
242019; (d) Taber, P. G.; Pfisterer, D. M.; Colberg, J. C.
Org. Process Res. Dev. 2004, 8, 385–388, Resolution of
[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]
methylamine with (R)-mandelic acid.
4. (a) Orlistat: Merck Index, 13ed., No. 6953, 2001; (b)
Karpf, M.; Zutter, U. EP 443449, 1991; Chem. Abstr.
1991, 115, 255980. Resolution of benzoic acid 1-(1-
carboxyheptyl)-3-phenoxymethyltetradecyl ester with (S)-
1-phenylethylamine.
5. (a) Duloxetine: Merck Index, 13ed., No. 3498, 2001; (b)
Berglund, R. A. EP 650965, U.S. 5,362,886, JP 1995-
188065, Chem. Abstr. 1994, 122, 132965. Resolution of 3-
(dimethylamino)-1-(2-thienyl)propan-1-ol with (S)-man-
delic acid; (c) Sakai, K.; Sakurai, R.; Yuzawa, A.;
Kobayashi, Y.; Saigo, K. Tetrahedron: Asymmetry 2003,
14, 1631–1636, Resolution of 3-(methylamino)-1-(2-thi-
enyl)propan-1-ol with (S)-mandelic acid.
20
D
(R)-1Æ(S)-2 salt: >99.9% de; mp 176.5–177.0ꢁC; ½a
¼
ꢀ45:7 (c 1.03, EtOH); IR (KBr) cmꢀ1: 3454, 2890,
2660, 2120, 1894, 1611, 1566, 1529, 1417, 1366, 1332,
1196, 1080, 1060, 937, 811, 787, 756, 703; 1H NMR
(400MHz, DMSO-d6): d 7.15–7.40 (m, 10H), 7.00 (d,
J = 8.0Hz, 2H), 6.92 (d, J = 8.0Hz, 2H), 4.65 (s, 1H),
4.28 (dd, J = 8.8, 6.0Hz, 1H), 3.07 (dd, J = 13.2,
6.0Hz, 1H), 2.94 (dd, J = 13.2, 8.8Hz, 1H), 2.21 (s,
3H). Anal. Calcd for C23H25NO3: C, 76.01; H, 6.93;
N, 3.85. Found C, 76.09; H, 6.98; N, 3.85.
4.4. X-ray crystal structure analysis
6. (a) Jacques, J.; Collet, A.; Wilen, S. H. Enantiomers,
Racemates, and Resolutions; Wiley: New York, 1981;
Crystallographic data for the structures of (R)-1Æ(S)-2
and (S)-1Æ(S)-2ÆH2O have been deposited with the Cam-
bridge Crystallographic Data Centre as reference num-
bers CCDC 241593and 241594, respectively. X-ray
diffraction data were measured using the Rigaku
RAXIS-RAPID system.
p
251; (b) Kozma, D. CRC Handbook of Optical
Resolution via Diastereomeric Salt Formation; CRC Press
LLC, 2002.
7. (a) Sakai, K. Symposium Molecular Chirality, Shizuoka,
Japan, IL-8, Oct 19, 2003; (b) Sakurai, R.; Sakai, K.;
Yuzawa, A.; Hirayama, N. Symposium Molecular Chiral-
ity, Shizuoka, Japan, PA-11, Oct 19, 2003.
8. Sakai, K.; Sakurai, R.; Yuzawa, A.; Hirayama, N.
Tetrahedron: Asymmetry 2003, 14, 3713–3718.
9. Sakai, K.; Sakurai, R.; Yuzawa, A.; Hatahira, K. Jpn.
Patent Appl. 2003-338118, 2003.
10. Sakai, K.; Sakurai, R.; Hirayama, N. Tetrahedron:
Asymmetry 2004, 15, 1073–1076.
11. Nohira, H.; Murata, H.; Asakura, I.; Terunuma, D. Japan
Patent Kokai 59-110656, 1984; Chem. Abstr. 1985, 102,
5896.
12. Asahara, S.; Tokura, N.; Okawara, M.; Kumanotani, J.;
Senoo, M. Solvent Handbook; Kodansha Scientific, 2001,
and references cited therein.
(R)-1Æ(S)-2: a colorless platelet single crystal of (S)-1Æ
(S)-2 salt (0.50 · 0.30 · 0.25mm) was grown from EtOH
using recrystallized salt crystals (>99.9% de). The X-ray
intensities were measured up to 2hmax = 68.17ꢁ with
graphite monochromated CuKa radiation (k =
˚
1.5419A) at 293K. C23H25NO3; formula weight
363.46; orthorhombic, P212121 (# 19), a = 6.607(4),
3
˚
˚
b = 15.504(1), c = 20.243(2)A, V = 2073(1)A , Z = 4,
Dcalc = 1.164g/cm3, R = 0.062; Rw = 0.053. Number of
reflections measured = total 2085, unique 1387.
13. Diastereomeric excess (% de) = [A ꢀ B] · 100/(A + B),
(S)-1Æ(S)-2ÆH2O: a colorless platelet single crystal of
(S)-1Æ(S)-2ÆH2O salt (0.30 · 0.25 · 0.15mm) was grown
from water using recrystallized salt crystals (>99.9%
de). The X-ray intensities were measured up
to 2hmax = 68.19ꢁ with graphite monochromated CuKa
where A and B are both diastereomers.
14. Resolution efficiency (E, %) = yield (%) · diastereomeric
excess (% de) · 2/100, where yield is calculated based on
(RS)-1.
15. (a) The values of dielectric constants of mixed solvents
were calculated as the weighted average of the mixture
components, alcohol and water, based on the following
˚
radiation (k = 1.5419A) at 293K. C23H27NO4; formula
weight 381.47; orthorhombic, P212121 (# 19),